Participated · Series A · Jan 2018

KBP Biosciences is a clinical-stage biotech founded in Jinan, China with a medicinal chemistry platform and preclinical development team focused on advancing novel small-molecule NCEs. Its lead program, KBP-5074, is a mineralocorticoid receptor antagonist for cardiovascular disease that is entering Phase 2b. The company also has KBP-7072, a 3rd‑generation aminomethylcycline that completed Phase 1 and holds FDA QIDP and Fast Track designations, and KBP-7026, a CRTH2 antagonist with an approved IND ready for Phase 1. KBP plans to open global corporate headquarters in the Greater Philadelphia Area and expand its US clinical, commercial and corporate capabilities. The company announced the appointment of Brian P. McVeigh as Chief Executive Officer to lead its global development and business‑development efforts. KBP says the Series A proceeds will be used to advance clinical development, expand operations and support other programs in the pipeline.

Participated · Equity · Apr 2014

Arrail Group is a Beijing-based dental services provider. The company provides dental care services in China. Arrail completed a Series E funding round that raised nearly $200 million. The round was led by Singapore state investor Temasek Holdings, per a company statement. The article does not disclose other participating investors, use of proceeds, or operating metrics. Founded in 1998, 瑞尔集团 operates a leading high-end oral healthcare chain in China under the brands “瑞尔” and “瑞泰”. The group runs nearly 100 clinics and hospitals across major cities including Beijing, Shanghai, Shenzhen, Guangzhou, Hangzhou, Xiamen, Tianjin, Chengdu, Chongqing, Xi'an, Qingdao, Ningbo, Changsha, Jinan and Wuxi, and has served over 5 million patient visits. Its core offering is professional mid-to-high-end dental care delivered through integrated clinics and hospitals staffed by experienced medical teams. Management emphasizes growing demand for quality dental services as incomes rise and positions the market as a large long-term opportunity. Following the financing, the company formally announced a “thousand-store plan,” targeting the opening of more than 1,000 clinics and hospitals nationwide within 5–8 years. The article highlights the company’s accumulated customer-relationship management, clinical capabilities, and its role as a private-sector leader in China’s dental market. 瑞尔齿科 provides dental and oral healthcare services and has built a 15-year reputation in the sector. The company announced a significant new financing round totaling $70 million. The infusion reflects growing private capital interest as national policies encourage private investment in medical services. Management says the financing will further consolidate 瑞尔齿科's leading position in the dental industry. The deal is expected to accelerate competition and consolidation within the oral healthcare market. 易凯资本 served as the company's exclusive financial advisor on the transaction. Founded in 1998, Rui'er Group operates a leading high-end dental clinic chain in China. The company runs 16 directly operated clinics across Beijing, Shanghai, Shenzhen and Xiamen and offers routine exams, cleaning and whitening, implants, orthodontics, cosmetic dentistry and pediatric dentistry. Rui'er is described in the articles as a recognized leader in China's high-end dental market based on its technical strength, service quality, scale and brand influence. The company completed a $20 million Series B financing in August 2011, reflecting strong market confidence. Rui'er expects to leverage the lead investor's healthcare experience and industry resources to accelerate business development. Yikai Capital acted as the exclusive financial adviser on the transaction. Arrail Dental operates a chain of high-end dental clinics providing international-standard dental care to China’s middle class and expatriates. Founded by Zou Qifang with its first clinic opened in April 1999 in Beijing, the group has expanded to 11 clinics across Beijing, Shanghai and Shenzhen. The company employs nearly 400 professional medical and management staff, about 60% of whom hold master’s or doctoral degrees. Arrail has established a leading brand position in China’s premium dental market. The recent transaction involved an equity restructuring and external financing intended to strengthen the company’s capital structure and support growth beyond directly operated high-end clinics. Management expects the new ownership structure and capital to pave the way for an eventual independent public listing and to enable broader partnerships with domestic and overseas dental schools, institutions and experts.